Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients’ health needs?

BACKGROUND: More than 6,800 rare diseases and conditions have been identified in the US, which affect 25–30 million Americans. In 1983, the US Congress enacted the Orphan Drug Act (ODA) to encourage the development and marketing of drugs to treat rare diseases and conditions. This study analyzed all...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodriguez-Monguio, R., Spargo, T., Seoane-Vazquez, E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217554/
https://www.ncbi.nlm.nih.gov/pubmed/28057032
http://dx.doi.org/10.1186/s13023-016-0551-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217554/
https://www.ncbi.nlm.nih.gov/pubmed/28057032
http://dx.doi.org/10.1186/s13023-016-0551-7

Ejemplares similares